AFP DEPARTMENT COLLECTION
FPIN's Clinical Inquiries
Clinical Inquiries from the Family Practice Inquiries Network (FPIN) provide short, concise, evidence-based answers to clinical questions common in family medicine. The answers include a summary of the evidence and commentary that puts the answers into perspective.
Apr 15, 2011 Issue
Secondary Causes of Obesity
There is little evidence about secondary causes of obesity in adults. The evaluation for secondary causes of obesity should include a patient history and physical examination, with additional laboratory testing based on specific symptoms, risk factors, and index of suspicion.
Apr 1, 2011 Issue
Appetite Suppressants as Adjuncts for Weight Loss
Phentermine and diethylpropion are appetite suppressants approved for use in the United States as adjuncts in the treatment of obesity. These agents demonstrate a modest weight loss benefit when combined with dietary modifications and exercise.
Mar 15, 2011 Issue
Antibiotics for Viral Upper Respiratory Tract Infections in Children
Antibiotic therapy does not benefit children with bronchiolitis, the common cold, or nonstreptococcal pharyngitis. If purulent rhinitis is present for more than 10 days, antibiotics shorten the duration of runny nose symptoms.
Jan 15, 2011 Issue
Reducing ACL Injuries in Female Athletes
Neuromuscular training programs that include plyometric and strengthening exercises significantly reduce noncontact ACL injuries in female soccer and handball players older than 14 years.
Dec 15, 2010 Issue
Thiazolidinedione Therapy for Managing Metabolic Syndrome
There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting.
Jun 15, 2010 Issue
Diagnosing Von Willebrand Disease
The diagnosis of vWD requires two clinical criteria: (1) a personal history, family history, or physical evidence of mucocutaneous bleeding and (2) a qualitative or quantitative decrease in functional activity of von Willebrand factor (vWF).